Global Parathyroid Disorders Market Size By Type (Simple Parathyroid Disorders, Complex Parathyroid Disorders), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Parathyroid Disorders Market was valued at USD X billion in 2023 and is projected to surpass USD X billion by 2031, growing at a CAGR of X% during the forecast period 2023-2031. Parathyroid disorders, including hyperparathyroidism, hypoparathyroidism, and parathyroid cancer, are increasingly diagnosed worldwide due to rising awareness, improved screening techniques, and an aging population prone to endocrine disorders.

The market growth is driven by advancements in diagnostic techniques, the introduction of novel therapies, and the increasing prevalence of chronic kidney disease (CKD), which is strongly associated with secondary hyperparathyroidism. The growing adoption of minimally invasive surgeries, such as parathyroidectomy, and the development of calcium-sensing receptor modulators further contribute to market expansion.

Drivers

Increasing Prevalence of Parathyroid Disorders

The rising incidence of primary and secondary hyperparathyroidism, particularly among aging populations and CKD patients, is fueling market growth. Studies suggest a significant increase in cases due to genetic predisposition, lifestyle changes, and the use of lithium-based medications.

Advancements in Diagnostic and Imaging Technologies

The introduction of high-sensitivity parathyroid hormone (PTH) assays, 4D CT scans, SPECT imaging, and ultrasound techniques has improved early detection rates and disease management. This has led to increased treatment adoption.

Growing Focus on Minimally Invasive Procedures

Minimally invasive parathyroidectomy (MIP) is becoming the standard treatment for hyperparathyroidism, offering reduced hospital stays and faster recovery times. The growing preference for robotic and endoscopic-assisted surgeries is further accelerating market growth.

Restraints

High Cost of Treatment and Diagnosis

Parathyroid disorder treatments, including surgical interventions, long-term medication, and diagnostic imaging, are expensive. The financial burden is particularly high in developing regions where healthcare infrastructure and reimbursement policies are inadequate.

Limited Awareness and Misdiagnosis

Due to the overlapping symptoms with other endocrine disorders, many cases of parathyroid dysfunction remain undiagnosed or are misdiagnosed. The lack of specialized endocrinologists in certain regions further hampers timely treatment.

Opportunities

Emerging Biologic and Targeted Therapies

The development of calcimimetics, monoclonal antibodies, and gene therapy solutions is revolutionizing parathyroid disorder treatment. Newer drugs such as etelcalcetide and evocalcet have demonstrated enhanced efficacy in managing secondary hyperparathyroidism in dialysis patients.

Expansion of Healthcare Infrastructure in Emerging Markets

The rapid growth of healthcare facilities in Asia-Pacific, Latin America, and the Middle East & Africa is creating a lucrative market for parathyroid disorder diagnostics and therapeutics. Increasing government initiatives and investments in public healthcare systems will drive further adoption.

Market by Disorder Type Insights

Hyperparathyroidism Segment Dominates the Market

Among different parathyroid disorders, hyperparathyroidism (primary, secondary, and tertiary) holds the largest market share due to its higher prevalence, particularly among postmenopausal women and CKD patients. Treatment advancements such as calcimimetics and parathyroidectomy procedures continue to drive segment growth.

Hypoparathyroidism Segment to Witness Rapid Growth

The hypoparathyroidism segment is expected to grow at the highest CAGR during the forecast period, driven by new drug approvals, increasing awareness, and a rising number of clinical trials for recombinant PTH therapies.

Market by Treatment Insights

Medications Segment Holds a Significant Share

Pharmaceutical treatments, including calcimimetics, vitamin D analogs, phosphate binders, and hormone replacement therapies, dominate the market. The introduction of novel biologics and gene therapies is expected to accelerate growth.

Surgical Treatment to Experience Steady Growth

Minimally invasive parathyroidectomy (MIP) remains a highly effective treatment for primary hyperparathyroidism, with ongoing advancements in robotic-assisted procedures enhancing patient outcomes.

Market by Regional Insights

North America Leads Due to High Awareness and Advanced Healthcare Infrastructure

North America dominates the global parathyroid disorders market due to well-established healthcare facilities, rising healthcare expenditure, and extensive research & development activities. The presence of leading biopharmaceutical companies further supports market expansion.

Asia-Pacific to Witness the Fastest Growth

Asia-Pacific is expected to register the highest growth rate due to rising healthcare investments, increasing prevalence of CKD, and expanding diagnostic capabilities. Government initiatives to enhance endocrine disorder management in China, India, and Japan are further propelling market demand.

Competitive Scenario

Key players in the Global Parathyroid Disorders Market include:

Amgen Inc.

OPKO Health Inc.

Ascendis Pharma A/S

Takeda Pharmaceutical Company Limited

Shire plc (Acquired by Takeda)

Sanofi S.A.

Fresenius Medical Care

Horizon Therapeutics plc

AbbVie Inc.

Calcilytix Therapeutics

These companies are actively investing in R&D activities, strategic collaborations, and new drug approvals to strengthen their market position. Recent developments include:

Amgen Inc. received FDA approval for etelcalcetide, a novel calcimimetic for secondary hyperparathyroidism.

Ascendis Pharma A/S initiated a Phase 3 trial for its long-acting PTH therapy for hypoparathyroidism.

Takeda Pharmaceutical Company Limited expanded its pipeline with novel formulations for calcium-sensing receptor modulators.

Scope of Work – Global Parathyroid Disorders Market

Report Metric Details

Market Size (2023) USD X billion

Projected Market Size (2031) USD X billion

CAGR (2023-2031) X%

Market Segments By Disorder Type (Hyperparathyroidism, Hypoparathyroidism, Parathyroid Cancer), By Treatment (Medications, Surgery)

Growth Drivers Increasing CKD Prevalence, Advancements in Diagnostics, Growing Adoption of Minimally Invasive Surgeries

Opportunities Expansion in Emerging Markets, Development of Novel Biologics and Gene Therapies

Key Market Developments

March 2023: Amgen Inc. launched a new clinical trial for an advanced calcimimetic drug aimed at improving secondary hyperparathyroidism treatment.

June 2023: OPKO Health Inc. announced the successful completion of Phase 3 trials for a recombinant parathyroid hormone (rPTH) therapy for hypoparathyroidism.

January 2024: Takeda Pharmaceutical Company Limited secured regulatory approval in Japan for a novel oral treatment targeting hyperparathyroidism-related bone loss.

FAQs

1. What is the current market size of the Global Parathyroid Disorders Market?

The market was valued at USD X billion in 2023 and is projected to expand significantly by 2031.

2. What is the major growth driver of the Global Parathyroid Disorders Market?

The increasing prevalence of parathyroid disorders, especially in CKD patients, along with advancements in diagnostic imaging and therapeutic options, are key growth drivers.

3. Which is the largest region during the forecast period in the Global Parathyroid Disorders Market?

North America is expected to dominate due to strong healthcare infrastructure, high awareness, and robust R&D investments.

4. Which segment accounted for the largest market share in the Global Parathyroid Disorders Market?

The hyperparathyroidism segment held the largest market share, owing to its high prevalence and growing treatment adoption.

5. Who are the key market players in the Global Parathyroid Disorders Market?

Key players include Amgen Inc., OPKO Health Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., and Horizon Therapeutics plc, among others.

This report provides an in-depth analysis of the Global Parathyroid Disorders Market, focusing on market dynamics, emerging trends, and competitive insights to aid stakeholders in making informed decisions. 🚀